Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

million (compared to euro 7,898 million in Q1 2010, including euro 513 million for Merial). Sales were up 0.1% excluding A/H1N1 sales and despite euro 569 million of sales lost in 2011 due to generic competition versus the comparable period in 2010.
  • Merial is now fully consolidated(4); sales were up 11.5% while business operating margin reached 36.7%.
  • Growth Platforms (excluding A/H1N1 sales) grew 15.5% and contributed 59.2% of Group sales in Q1 2011 versus 51.4% in Q1 2010.
  • Emerging Markets(5) sales reached euro 2,386 million, up 14.6% (excluding A/H1N1 sales), exceeding the U.S. and Western Europe and accounted for 30.7% of Group sales.
  • Business EPS(1) was euro 1.66, down 16.1% at CER. Excluding A/H1N1 sales, decrease in business EPS(1) was limited to 6.0% at CER.
  • Free cash flow was stable at euro 2,006 million, and the Group had a positive net cash position at the end of Q1 2011 prior to the Genzyme acquisition in April.

  • Outlook

  • The Group is on track to achieve previously announced cost savings of euro 2 billion(6) per year by end of 2011.
  • Regulatory filings for 3 major late-stage pipeline projects (lixisenatide, alemtuzumab and teriflunomide) are expected in the next 12 months. Aflibercept showed positive Phase III results in second-line metastatic colorectal cancer.
  • The acquisition of Genzyme adds a new growth platform and a global center for excellence in rare diseases. This transaction is an important achievement of the Group's sustainable growth strategy.
  • Full year 2011 guidance provided earlier this year will be reviewed at half-year results.
  • (1) See Appendix 9 for definitions of financial indicators; (2) Constant Exchange Rates; (3) Growth in net sales is expressed at constant exchang
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

    Related medicine technology :

    1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
    6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
    7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
    8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
    10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
    11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic Acids, ... by Region ( North America , ... of the World) - Global Trends and Forecast to 2020", ... at USD 4.62 Billion in 2014 and is projected to ... 7.4% from 2015 to 2020. Browse 77 ...
    (Date:8/27/2015)... 2015  The Academy of Managed Care Pharmacy ... (FDA,s) draft guidance and proposed rule that calls ... bear a nonproprietary name with an FDA-designated suffix. ... decision from the FDA on the naming issue ... urging the agency to use the same nonproprietary ...
    (Date:8/27/2015)... ieCrowd™ today announced the achievement of ... the company,s supplemental oxygen delivery device, Smart Oxygen ... by ieCrowd,s subsidiary Smart Oxygen Solutions TM , ... oxygen based on level of activity.  The FDA ... Smart Oxygen device would require a series of ...
    Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
    ... 2011 The U.S. Food and Drug Administration today approved ... patients at risk of stroke due to clogged neck arteries ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The carotid arteries ... brain. The blood flow in the arteries can become partially ...
    ... May 6, 2011 On Thursday, the U.S. Food ... with progressive neuroendocrine tumors located in the pancreas (PNET) ... spread to other parts of the body (metastatic).   ... tumors found in the pancreas are slow-growing and rare. ...
    Cached Medicine Technology:FDA Expands Approved Use For Carotid Stent 2FDA Expands Approved Use For Carotid Stent 3FDA Approves New Treatment for Rare Type of Pancreatic Cancer 2
    (Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
    (Date:8/28/2015)... Church, VA (PRWEB) , ... ... ... Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and Best ... Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned ...
    (Date:8/28/2015)... ... 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance ... A Mission” benefit concert in Mendon, IL. Held in the Show Barn at the ... music education programs in the underfunded local school districts of Mendon at neighboring Quincy, ...
    (Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this software allows businesses to track product movement from beginning to ...
    (Date:8/28/2015)... , ... August 28, 2015 , ... Medical Solutions, one ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will be ... , Now in its eighth year, the Best Places to Work in Healthcare program ...
    Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3
    ... What: Georgetown,s Lombardi Comprehensive Cancer Center and Capital Breast ... of providing breast cancer screening to underserved women at ... DC. This is the second year the AVON Foundation ... Capital Breast Care Center to their dedication to breast ...
    ... May 1, Binax, Inc., a leading provider ... identify the causative pathogens of infectious diseases, announced that it ... to customers and potential customers of the BinaxNow(R) Influenza A ... A & B test has not been validated for detection ...
    ... greatly improved when doctors implemented a series of ... unit. Yale School of Medicine researchers report their ... American Journal of Obstetrics & Gynecology . ... determine if improving communication between medical staff and ...
    ... malignancies among older men , , FRIDAY, May 1 ... chronic kidney disease appear to have a higher risk ... Australian scientists report. , The observation -- which suggests ... cancer, but not prostate cancer -- adds to previous ...
    ... HAMILTON, Bermuda, May 1 Warner Chilcott Limited (Nasdaq: ... its subsidiaries and Mayne Pharma International Pty. Ltd. ("Mayne") ... and Mylan Inc. ("Mylan") in the District Court for ... U.S. Patent No. 6,958,161 (the ",161 Patent") which covers ...
    ... have embraced a simple and direct model of the disease ... bearing total responsibility for the spread of cancer to distant ... grew, and reproduced. The result was a seed-dominant model that ... tumor seed but neglecting the role of the soil. , ...
    Cached Medicine News:Health News:Lombardi Cancer Center and the Capital Breast Care Center awarded $750,000 from the AVON Foundation 2Health News:Obstetrical unit at Yale-New Haven Hospital achieves dramatic improvement in patient safety 2Health News:Chronic Kidney Disease Raises Risk for Some Cancers 2Health News:Chronic Kidney Disease Raises Risk for Some Cancers 3Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 2Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 3Health News:Where tumor cells boldly go: Weill Cornell cancer biologists shed light on the metastatic niche 2
    Inquire...
    The Perfect Vac Quad Manifold allows one to four 96-well plates to be processed simultaneously. A single plate may be processed in 30 minutes; four plates are processed in 45 minutes....
    ... Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous acclaim ... ... ... ...
    The Empore 96 well plate vacuum manifold comes complete with waste tray, gasket and shims, may be used as a stand-alone or with 96-well automation....
    Medicine Products: